Background: Quetiapine fumarate, a 2nd generation anti-… at developing, and characterising
potentially lymphatic absorbable Solid Lipid Nanoparticles (SLN) of quetiapine fumarate by …

… in vitro release values is realized with the help of mathematical polynomial equations that
convert the dissolution profiles into parameters relating to the pharmaceutical characteristics of …

… The potential impurities of quetiapine fumarate were … to develop a new LC/MS/MS method
for separation and quantitative determination of related substances in quetiapine fumarate. …

… Quetiapine fumarate has possessed low solubility and … Solubility of quetiapine was assessed
in various liquid vehicles (oils, … focused on the development of quetiapine loaded SMEDDS. …

… The objective of this work was to develop a new nanostructured lipid carrier (NLC) formulation
for the oral delivery of quetiapine fumarate (QTF) and assess the drug’s in vitro release …

… development and characterization of the sustained release mucoadhesive microspheres of
quetiapine fumarate… biopharmaceutical attributes of quetiapine fumarate from mucoadhesive …

… A series of studies were conducted to guide the development and characterise the
pharmacokinetics of extended-release quetiapine fumarate (quetiapine XR), a once-daily formulation …

… Quetiapine fumarate is an atypical antipsychotic drug used to treat schizophrenia, mania …
Quetiapine was developed in 1985 and approved for medical use in the USA in 1997. …

… of quetiapine fumarate by incorporating in solid lipid nanoparticles (SLN). Six quetiapine
fumarate SLN formulations were developed … Stable quetiapine fumarate SLNs having a mean …

… to develop and characterize an oral sustain release drug delivery system for commonly
prescribed antipsychotic Quetiapine fumarate. … K100 LV and K4M CR was developed using wet …